Table 2.
ACE(µM/g) | AD(ng/g) | NAD(ng/g) | 5-HT(ng/g) | HS(ng/g) | DA(ng/g) | GABA (ng/g) | |
---|---|---|---|---|---|---|---|
G0 | 1.5±0.2 | 5.3±0.2 | 4.3±0.1 | 3.3±0.1 | 7.8±0.1 | 18.2±0.1 | 61.5±0.2 |
G1 | 1.7±0.2# | 5.6±0.1# | 4.5±0.2# | 3.3±0.2# | 7.4±0.1# | 16.0±0.2# | 62.9±0.2# |
G2 | 0.8±0.2* | 5.1±0.2 * | 3.8±0.1* | 3.8±0.1* | 9.7±0.1* | 20.4±0.3* | 54.6±0.3* |
G3 | 1.4±0.1# | 5.4±0.2# | 4.6±0.1# | 3.2±0.1# | 7.3±0.1# | 17.6±0.2# | 58. 0±0.1# |
G4 | 1.1±0.1* | 4.3±0.2* | 4.1±0.1* | 4.0±0.1* | 9.1±0.1* | 24.9±0.4* | 52. ±0.2* |
G5 | 1.2±0.1* | 5.3±0.6# | 4.4±0.1# | 3.2±0.1# | 7.0±0.1* | 21.0±0.4* | 57.9±0.2# |
G6 | 1.2±0.1* | 4.0±0.2* | 3.7±0.1* | 3.1±0.1# | 8.9±0.1* | 26.3±0.1* | 54.1±0.1* |
G7 | 1.3±0.4* | 5.2±0.1# | 4.3±0.1# | 3.2±0.1# | 6.9±0.1* | 22.1±0.1* | 56.9±0.4* |
MANOVA application and F value were determined, *Significant at P < 0.05, # Non-significant at P < 0.05. Replicates 5 per each. Abbreviations: G0, control; G1, Morus alba-treatment; G2, Experimental hypercholesterolemic; G3, Experimental hypercholesterolemia + Morus alba-treatment; G4, Experimental diabetic; G5, Diabetic + Morus alba-treatment; G6, Hypercholesterolemic and diabetic; G7, Hypercholesterolemic and diabetic + Morus alba.